This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Valsartan

Read time: 1 mins
Marketing start date: 04 Apr 2025
...
 

Summary of product characteristics


Effective Time

20240723

Version

1

Spl Product Data Elements

Valsartan Valsartan VALSARTAN VALSARTAN CROSPOVIDONE FERRIC OXIDE YELLOW HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL 6000 SILICON DIOXIDE TALC TITANIUM DIOXIDE light yellow to yellow T;4 Valsartan Valsartan VALSARTAN VALSARTAN CROSPOVIDONE FERRIC OXIDE RED FERRIC OXIDE YELLOW HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL 6000 SILICON DIOXIDE TALC TITANIUM DIOXIDE light pink to pink T7 Valsartan Valsartan VALSARTAN VALSARTAN CROSPOVIDONE FERRIC OXIDE YELLOW HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL 6000 SILICON DIOXIDE TALC TITANIUM DIOXIDE light yellow to yellow 277 Valsartan Valsartan VALSARTAN VALSARTAN CROSPOVIDONE FERRIC OXIDE RED FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL 6000 SILICON DIOXIDE TALC TITANIUM DIOXIDE light brown to brown 278

Application Number

ANDA218991

Brand Name

Valsartan

Generic Name

Valsartan

Product Ndc

70771-1884

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Valsartan tablets USP, 40 mg NDC 70771-1882-3 Bottle of 30 Scored Tablets Rx only Valsartan tablets USP, 80 mg NDC 70771-1883-9 Bottle of 90 tablets Rx only Valsartan tablets USP, 160 mg NDC 70771-1884-9 Bottle of 90 tablets Rx only Valsartan tablets USP, 320 mg NDC 70771-1885-9 Bottle of 90 tablets Rx only 40 mg 80 mg 160 mg 320 mg

Spl Unclassified Section

SPL UNCLASSIFIED

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.